Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2016-02-01 Director's Dealing
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2016-02-01 English
FORM 4 SUBMISSION
Director's Dealing
2016-02-01 English
FORM 4 SUBMISSION
Director's Dealing
2016-02-01 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 25, 2016, by Novavax, Inc. It reports the entry into a material definitive agreement related to the sale of $300 million aggregate principal amount of 3.75% Convertible Senior Notes due 2023. The document details the terms of the Purchase Agreement, the Indenture and Notes, and related capped call transactions. It also includes information about the issuance of the Notes in a private placement and references forward-looking statements and risk factors. The content focuses on financing activities, specifically the issuance of convertible notes and related transactions. There is no indication that this is a full annual or quarterly report, audit report, earnings release, or other types of filings. The detailed description of the financing transaction and related agreements fits the definition of a Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement of a report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2016-01-29 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-01-27 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 25, 2016, by Novavax, Inc. It contains a section titled 'Item 2.02. Results of Operations and Financial Condition,' which provides preliminary financial information about cash and cash equivalents as of December 31, 2015. The document explicitly states that the full financial results for the fiscal year ended December 31, 2015, have not been finalized and that the information is preliminary and unaudited. The document is a current report providing an update on financial condition but does not contain comprehensive financial statements or detailed analysis typical of an Annual Report (10-K) or an Interim Report (IR). It is a regulatory filing to inform investors of material events or updates. Given the nature of the document as a Form 8-K current report with preliminary financial information, it fits best under the category of Regulatory Filings (RNS).
2016-01-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.